Loading stock data…
APGE
$85.00+1.99 (+2.40%)
Market ClosedLast close Jun 9
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Apogee Therapeutics, Inc. in the Healthcare sector is trading at $85.00. Wall Street consensus targets $118.35 (17 analysts), implying a +39.2% move over the next 12 months. The stock is currently near its 52-week high of $95.31, remaining 25.7% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +39.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$85.00
Potential Downside
0%
Whystock Fair Value$85.00
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus17 analysts
Mean target$118.35+39.2%
Range$81.00 – $160.00
Fundamentals
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indicat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-21.87%
Volume
Today's trading volume
630,277
Recent News
Apogee (APGE) Secures Up to $1.3B in Non-Dilutive Financing from Blackstone to Advance Zumilokibart
Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best high short interest stocks with highest upside potential. On May 27, Apogee Therapeutics secured $1.3 billion in non-dilutive financing from Blackstone Life Sciences to fund Phase 3 development and commercialization of zumilokibart. The deal includes $800 million in synthetic royalties and $500 million in senior debt, […]
Apogee Therapeutics Readies Zumi for Phase 3 With Blackstone Backing
Apogee Therapeutics (NASDAQ:APGE) executives said the company is preparing to move its lead drug candidate, zumilokibart, into Phase 3 testing later this year after reporting Phase 2b data in atopic dermatitis and securing a major financing agreement with Blackstone. Speaking at a Jefferies-hosted
Assessing Apogee Therapeutics (APGE) Valuation After Positive Phase 2 APEX Results For Zumilokibart
Apogee Therapeutics (APGE) is in focus after reporting statistically significant 16-week Phase 2 APEX data for zumilokibart in moderate-to-severe atopic dermatitis, along with detailed plans to move the candidate into Phase 3 development. See our latest analysis for Apogee Therapeutics. The positive APEX update and detailed Phase 3 roadmap arrive after a period of strong stock performance, with a 90 day share price return of 15.83% and a 1 year total shareholder return of 124.18%. This...
Apogee Therapeutics lines up $1.3B strategic financing for zumilokibart program
Apogee Enterprises (NASDAQ:APOG) has entered a strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion in non-dilutive capital, combining up to $800 million in synthetic royalty financing with as much as $500 million in senior corporate debt, giving the immunology...
Why Apogee Slipped On Its Dupixent-Rivaling Eczema Results
Apogee Therapeutics revealed mixed results for its experimental eczema treatment Wednesday, and the stock dropped.